Pyrazole Bioisosteres of Leflunomide as B-Cell Immunosuppressants for Xenotransplantation and Chronic Rejection: Scope and Limitations
- 1 August 1998
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 41 (18), 3530-3538
- https://doi.org/10.1021/jm981028c
Abstract
T-cell immunosuppressant-based therapies efficiently control early graft rejection in allotransplantation settings. They fail, however, to prevent those rejection events which are mediated by transplant-induced antibody (Ab) responses such as those involved in xenograft and chronic allograft rejection. This is mainly due to their inability to block T-cell-independent Ab production against the transplanted organs. The bioactive metabolite 2( Z ) of leflunomide (1) inhibits the formation of such Ab, but the drug has pharmacokinetic properties and a therapeutic window incompatible with transplantation indications. Pyrazole 3, a constrained analogue of 2( Z ), was designed and shown to be conformationally and biologically similar to 2( Z ). Further investigations with derivatives of 3 demonstrated that the pyrazoles had very tight structure−activity relationships, the only equipotent compound being 3o. However, in contrast to 2( Z ), both 3 and 3o were inactive in vivo due to short half-life and drug concentrations lower than the in vitro obtained IC50 values. Compound 3o inhibits T-cell-independent Ab production by a different biochemical mechanism from that of 2( Z ) and 3 and may therefore represent a valuable tool for the identification of new targets for B-cell inhibition.Keywords
This publication has 7 references indexed in Scilit:
- 3‐Hydroxy‐2‐cyanoalk‐2‐enamides, and 2‐Cyano‐2‐(tetrahydrofuran‐2‐ylidene)‐ and 2‐Cyano‐2‐(tetrahydropyran‐2‐ylidene)acetamides: Synthesis, structure, and solvent‐dependent (Z)/(E)‐isomerismHelvetica Chimica Acta, 1998
- Strategies for preventing porcine xenograft rejection: recent progress and future developmentsExpert Opinion on Therapeutic Patents, 1997
- Prevention of Transplant RejectionDrugs, 1997
- Leflunomide's Bioactive Metabolite Has the Minimal Structural Requirements for the Efficient Inhibition of Human Dihydroorotate DehydrogenaseBioorganic Chemistry, 1997
- A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive DrugJournal of Medicinal Chemistry, 1997
- Leflunomide and malononitriloamidesExpert Opinion on Investigational Drugs, 1997
- Kinetics and mechanism of oxidation of aromatic hydrocarbons by Ru(trpy)(bpy)O2+Journal of the American Chemical Society, 1982